Ana Monfort-Vengut

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 5

Top Topics

Transcription Factor

Top Venues

Molecular oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Carlos Marugán, Natalia Sanz-Gómez, Beatriz Ortigosa, Ana Monfort-Vengut, Cristina Bertinetti, Ana Teijo, Marta González, Alicia Alonso de la Vega, María José Lallena, Gema Moreno-Bueno, Guillermo de Cárcer
TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling. Molecular oncology (2024)
Carlos Marugán, Natalia Sanz-Gómez, Beatriz Ortigosa, Ana Monfort-Vengut, Cristina Bertinetti, Ana Teijo, Marta González, Alicia Alonso de la Vega, María José Lallena, Gema Moreno-Bueno, Guillermo de Cárcer
TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling. Molecular oncology 18 (6) (2024)
Carlos Marugán, Natalia Sanz-Gómez, Beatriz Ortigosa, Ana Monfort-Vengut, Cristina Bertinetti, Ana Teijo, Marta González, Alicia Alonso de la Vega, María José Lallena, Gema Moreno-Bueno, Guillermo de Cárcer
TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling. Molecular oncology 18 (6) (2024)
Carlos Marugán, Natalia Sanz-Gómez, Beatriz Ortigosa, Ana Monfort-Vengut, Cristina Bertinetti, Ana Teijo, Marta González, Alicia Alonso de la Vega, María José Lallena, Gema Moreno-Bueno, Guillermo de Cárcer
TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling. Molecular oncology 18 (6) (2024)
Carlos Marugán, Natalia Sanz-Gómez, Beatriz Ortigosa, Ana Monfort-Vengut, Cristina Bertinetti, Ana Teijo, Marta González, Alicia Alonso de la Vega, María José Lallena, Gema Moreno-Bueno, Guillermo de Cárcer
TPX2 overexpression promotes sensitivity to dasatinib in breast cancer by activating YAP transcriptional signaling. Molecular oncology 18 (6) (2024)